Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma
NCT ID: NCT06645951
Last Updated: 2025-01-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
300 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-11-04
Study Completion Date
2034-11-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this observational study is to create, manage and analyze a multicenter national database of patients with parathyroid carcinoma or atypical parathyroid adenoma, aimed at collecting and studying anamnestic, diagnostic, genetic, clinical, histological, and therapeutic data in a relatively wide number of patients in Italy.
The study will include 33 specialist clinical centers of endocrinology and endocrine surgery, located throughout the Italian territory, and to which patients refer from all the 20 regions of Italy.
Data will be collected over time, both in retrospective and prospective manners, during the 10-year duration of the study, starting from the recruiting visit (basal visit) and then during each follow-up visits patients will undergo for the control of disease progression at the recruiting clinical centers.
Collected data will include both the most classic traits of the pathology and the less common ones, with the final goal of refining and deepening medical knowledge in the field of these two extremely rare parathyroid cancers and be able to define optimal clinical and therapeutic management of patients, improving their quality and life expectancy.
The main aspects this observational study aims to assess and clarify are:
1. Evaluation of prevalence and incidence of parathyroid carcinoma and atypical parathyroid adenoma in Italy, both as sporadic disease or in the context of genetic disorders.
2. Clinical, histological, and biochemical characterization of parathyroid carcinoma vs atypical parathyroid adenoma, to assess features and aspects that distinguish these two kinds of tumors and may help in the differential diagnosis.
3. Evaluation of short-term and long-term response to therapies in patients with parathyroid carcinoma and in patients with atypical parathyroid adenoma to assess possible differences between these two types of cancer and, thus, to design tailored clinical and therapeutic managements for patients.
4. Evaluation of short-term and long-term response to therapies in sporadic forms vs genetic forms of parathyroid carcinoma and atypical parathyroid adenoma, to assess possible differences between these two different forms of diseases and, thus, to design tailored clinical and therapeutic managements for patients.
The study will include two independent cohorts of female and male patients of any age, one including patients who developed parathyroid carcinoma (cohort 1) and one including patients who developed atypical parathyroid adenoma (cohort 2), both as sporadic cancer or in the context of genetic diseases. The study does not include either any control group/comparison group or healthy volunteers.
The study itself does not involve any medical intervention or drug administration. Treatments (surgery and/or drugs), for which data on response to therapy will be collected in the database, are those that are conventionally used in patients with parathyroid carcinoma or atypical parathyroid adenoma for treatment of their pathology, regardless of their inclusion in this observational study.
The study will include 33 specialist clinical centers of endocrinology and endocrine surgery, located throughout the Italian territory, and to which patients refer from all the 20 regions of Italy.
Data will be collected over time, both in retrospective and prospective manners, during the 10-year duration of the study, starting from the recruiting visit (basal visit) and then during each follow-up visits patients will undergo for the control of disease progression at the recruiting clinical centers.
Collected data will include both the most classic traits of the pathology and the less common ones, with the final goal of refining and deepening medical knowledge in the field of these two extremely rare parathyroid cancers and be able to define optimal clinical and therapeutic management of patients, improving their quality and life expectancy.
The main aspects this observational study aims to assess and clarify are:
1. Evaluation of prevalence and incidence of parathyroid carcinoma and atypical parathyroid adenoma in Italy, both as sporadic disease or in the context of genetic disorders.
2. Clinical, histological, and biochemical characterization of parathyroid carcinoma vs atypical parathyroid adenoma, to assess features and aspects that distinguish these two kinds of tumors and may help in the differential diagnosis.
3. Evaluation of short-term and long-term response to therapies in patients with parathyroid carcinoma and in patients with atypical parathyroid adenoma to assess possible differences between these two types of cancer and, thus, to design tailored clinical and therapeutic managements for patients.
4. Evaluation of short-term and long-term response to therapies in sporadic forms vs genetic forms of parathyroid carcinoma and atypical parathyroid adenoma, to assess possible differences between these two different forms of diseases and, thus, to design tailored clinical and therapeutic managements for patients.
The study will include two independent cohorts of female and male patients of any age, one including patients who developed parathyroid carcinoma (cohort 1) and one including patients who developed atypical parathyroid adenoma (cohort 2), both as sporadic cancer or in the context of genetic diseases. The study does not include either any control group/comparison group or healthy volunteers.
The study itself does not involve any medical intervention or drug administration. Treatments (surgery and/or drugs), for which data on response to therapy will be collected in the database, are those that are conventionally used in patients with parathyroid carcinoma or atypical parathyroid adenoma for treatment of their pathology, regardless of their inclusion in this observational study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Establishment of a Registry of Patients With Parathyroid Disease
NCT06797934
Hyperparathyroidism
Hypoparathyroidism
RECRUITING
Study of the Prevalence of Osteo-metabolic Complications in Patients With Thyroid Cancer
NCT06627998
Cancer of Thyroid
Vertebral Fracture
Osteoporosis
RECRUITING
Studies of Elevated Parathyroid Activity
NCT00001277
Hyperparathyroidism
Hypercalcemia
Parathyroid Neoplasm
+2 more
COMPLETED
PHASE2
Study of Clinical Outcomes of Thyroid Cancer
NCT04031339
Thyroid Neoplasms
UNKNOWN
Observational Study on Thyroid Tumors and EvaLuation of the roLe of New pOntential Predictive/Prognostic Factors
NCT07064369
Carcinoma of Head/Neck
ENROLLING_BY_INVITATION
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A. Background and rationale:
Parathyroid carcinoma (PC) and atypical parathyroid adenoma (aPA) are two extremely rare forms of cancer of the parathyroid glands, that represent approximately 1% of all parathyroid tumors.
The extreme rarity of these two types of tumor results in a lack of specific and detailed clinical information on them. This, together with the current scarcity and incompleteness of multicenter and prospective studies on large case series, has not yet allowed to reach a shared consensus for the clinical and therapeutic management and follow-up of these tumors, nor the creation of specific guidelines. For this reason, the institution and management of national multicenter databases of patients with parathyroid carcinoma or atypical parathyroid adenoma are extremely important to allow the collection of a relatively high number of patients with these two endocrine cancers, whose clinical features could be, then, carefully studied in every aspect of the disease, from the most classic traits of the pathology to the less common ones, in both retrospective and prospective manners.
B. Main aim and specific objectives:
Main goal of this observational study is to create, manage and analyze a retro-prospective multicenter national database of patients with parathyroid carcinoma or atypical parathyroid adenoma in Italy, aimed at collecting and studying anamnestic, diagnostic, genetic, clinical, histological, and therapeutic data on these two extremely rare parathyroid cancers in a relatively wide number of patients.
Such a database will allow for an epidemiological evaluation of the prevalence and incidence of parathyroid carcinoma and atypical parathyroid adenoma in Italy, and to collect case history of patients whose clinical cases will be studied in detail and followed over time up to 10 years after the recruitment in the study, also as post-operative follow-up, in order to refine knowledge in the field of these two rare and malignant parathyroid tumors, to identify the most effective therapy, and direct future research in the identification of possible specific therapeutic targets.
Specific objectives of the studies are:
1. Creation of an Italian centralized multicenter database of patients with parathyroid carcinoma or atypical parathyroid adenoma, through the collection of patients at 33 specialist clinical centers of endocrinology and endocrine surgery, located throughout the Italian territory and visiting patients from all the 20 regions of Italy.
2. Collection of a relatively high number of patients with parathyroid carcinoma or atypical parathyroid adenoma, both as sporadic tumors or in the context of genetic disorders.
3. Retrospective collection of data about past clinical history of parathyroid carcinoma and atypical parathyroid adenoma, at the time of the recruiting visit.
4. Continuous and updated prospective collection of patients' data over time, starting from the first recruiting visit up to 10 years after the recruitment in the study.
5. Evaluation of the prevalence and incidence of parathyroid carcinoma and atypical parathyroid adenoma in Italy, both as sporadic disease or in the context of genetic disorders.
6. Clinical, histological and biochemical characterization of parathyroid carcinoma vs atypical parathyroid adenoma, to assess features and aspects that distinguish these two kinds of tumors and may help in the differential diagnosis.
7. Evaluation of short-term and long-term response to therapies in patients with parathyroid carcinoma and in patients with atypical parathyroid adenoma to assess possible differences between these two types of cancer and, thus, to design tailored clinical and therapeutic managements for patients.
8. Evaluation of short-term and long-term response to therapies in sporadic forms vs genetic forms of parathyroid carcinoma and atypical parathyroid adenoma, to assess possible differences between these two different forms of diseases and, thus, to design tailored clinical and therapeutic managements for patients.
C. Study population:
The study will include two independent cohorts of female and male patients of any age, one including patients who developed parathyroid carcinoma (cohort 1) and one including patients who developed atypical parathyroid adenoma (cohort 2), both as sporadic cancer or in the context of genetic diseases.
The study does not include either any control group/comparison group or healthy volunteers.
Given the extreme rarity of parathyroid carcinoma and atypical parathyroid adenoma, we estimate that we will be able to include in the study a minimum of 100 and a maximum of 300 patients affected by parathyroid carcinoma or atypical parathyroid adenoma during the 10 years of the study.
Inclusion criteria
* Cohort 1: parathyroid carcinoma
* Cohort 2: atypical parathyroid adenoma Exclusion criteria
* None
D. Study design and setting:
Non-profit, multicenter, national, retro-prospective, observational study, consisting in the design, creation, management and analysis of an Italian database of patients with parathyroid carcinoma or atypical parathyroid adenoma.
The study will last 10 years. The enrollment of patients with parathyroid carcinoma or atypical parathyroid adenoma, the inclusion in the database with retrospective collection of their clinical data, and the subsequent prospective collection of clinical follow-up data will take place throughout the duration of the study. For the retrospective collection, retrospective data on parathyroid carcinoma or atypical parathyroid adenoma will be retrieved from patient's medical records, at the time of the medical visit that the patient will carry out at the Clinical Center for the evaluation of his/her parathyroid disease, regardless of inclusion in this study. Prospective data relating to the tumor follow-up will be collected during the subsequent medical follow-up visits, scheduled for each patient as part of the clinical management of his/her parathyroid disease, regardless of inclusion in this study.
Being an observational study, this study itself does not involve the administration of any drug, nor the use of any medical device, nor does it involve additional medical visits, clinical analyses or care procedures in addition to those conventionally scheduled for the clinical and therapeutic management of patient affected by parathyroid carcinoma or atypical parathyroid adenoma. No participant biospecimens of any type will be collected and retained to perform this study. Pharmacological treatments and parathyroid surgery, for which data on response to therapy and peri-operative and post-operative outcomes will be collected in the database during the study, are those that are conventionally administered and performed in patients with parathyroid carcinoma or atypical parathyroid adenoma in the context of treatment of their pathology, regardless of their inclusion in this observational study.
All data will be collected anonymously, and they will be analyzed as aggregates. Data collected in the database will be, first, processed using descriptive statistics, such as frequency tables for categorical data, median and quartiles for quantitative data on ordinal scales and mean and standard deviation for quantitative data on metric scales. Secondly, the correlations between variables will be evaluated using the Pearson correlation index in the case of continuous variables and the chi-square test for categorical variables.
E. Data and variables:
Data collected in the database will include (if available in patient's medical records):
* Demographics (sex, year of birth)
* Family history of parathyroid carcinoma/atypical parathyroid adenoma or other parathyroid diseases in first-degree relatives
* Lifestyle habits (i.e smoke, alcohol intake)
* History of neck irradiation
* Clinical history and therapy of hyperparathyroidism prior to diagnosis of parathyroid carcinoma/atypical parathyroid adenoma
* Presence of comorbidities
* Age at diagnosis of parathyroid carcinoma/atypical parathyroid adenoma, type of diagnosis, genetic test (if performed)
* Clinical manifestations of parathyroid carcinoma/atypical parathyroid adenoma (i.e hypercalcemia, nephrolithiasis, nephrocalcinosis, bone mass loss, fragility fracture, bone pain, radiological findings of skeletal complaints, gastrointestinal manifestations)
* Pre-operative instrumental screening of the neck (neck ultrasounds, parathyroid scintigraphy with 99mTc-Sestamibi, neck CT scan, 11C-choline PET/CT, 11C-methionin PET/CT, 18F-FDG-PET/CT)
* Pre-operative biochemical measurements of parameters of parathyroid function and of bone and mineral metabolism
* Pre-operative DXA evaluation of bone status
* Pre-operative identification of lymph node and/or distant metastases
* Pharmacological therapies
* Surgical intervention (age, type, clear margins, removed lymph nodes, complications, perioperative mortality, etc)
* Post-operative histological analysis of resected tumor (surrounding tissue and vascular invasion, Ki67 index, mitotic activity, nuclear atypia, aneuploidy, immunostaining of parafibromin and other specific proteins)
* TMN tumor staging
* Somatic genetic screening of resected tumor
* Post-operative clinical follow-up (serum calcium normalization, post-operative hypoparathyroidism, episodes of hypocalcemia, episodes of hypophosphatemia, hungry bone syndrome, disease persistence, tumor recurrence, etc)
* Post-operative biochemical measurements of parameters of parathyroid function and of bone and mineral metabolism (the first check-up after parathyroid surgery, and subsequent follow-up measurements)
* Post-operative instrumental screening of the neck (neck ultrasounds, parathyroid scintigraphy with 99mTc-Sestamibi, neck CT scan, 11C-choline PET/CT, 11C-methionin PET/CT, 18F-FDG-PET/CT)
* Post-operative DXA evaluation of bone status
* Death as a consequence of carcinoma/atypical parathyroid adenoma (age of death, cause)
Parathyroid carcinoma (PC) and atypical parathyroid adenoma (aPA) are two extremely rare forms of cancer of the parathyroid glands, that represent approximately 1% of all parathyroid tumors.
The extreme rarity of these two types of tumor results in a lack of specific and detailed clinical information on them. This, together with the current scarcity and incompleteness of multicenter and prospective studies on large case series, has not yet allowed to reach a shared consensus for the clinical and therapeutic management and follow-up of these tumors, nor the creation of specific guidelines. For this reason, the institution and management of national multicenter databases of patients with parathyroid carcinoma or atypical parathyroid adenoma are extremely important to allow the collection of a relatively high number of patients with these two endocrine cancers, whose clinical features could be, then, carefully studied in every aspect of the disease, from the most classic traits of the pathology to the less common ones, in both retrospective and prospective manners.
B. Main aim and specific objectives:
Main goal of this observational study is to create, manage and analyze a retro-prospective multicenter national database of patients with parathyroid carcinoma or atypical parathyroid adenoma in Italy, aimed at collecting and studying anamnestic, diagnostic, genetic, clinical, histological, and therapeutic data on these two extremely rare parathyroid cancers in a relatively wide number of patients.
Such a database will allow for an epidemiological evaluation of the prevalence and incidence of parathyroid carcinoma and atypical parathyroid adenoma in Italy, and to collect case history of patients whose clinical cases will be studied in detail and followed over time up to 10 years after the recruitment in the study, also as post-operative follow-up, in order to refine knowledge in the field of these two rare and malignant parathyroid tumors, to identify the most effective therapy, and direct future research in the identification of possible specific therapeutic targets.
Specific objectives of the studies are:
1. Creation of an Italian centralized multicenter database of patients with parathyroid carcinoma or atypical parathyroid adenoma, through the collection of patients at 33 specialist clinical centers of endocrinology and endocrine surgery, located throughout the Italian territory and visiting patients from all the 20 regions of Italy.
2. Collection of a relatively high number of patients with parathyroid carcinoma or atypical parathyroid adenoma, both as sporadic tumors or in the context of genetic disorders.
3. Retrospective collection of data about past clinical history of parathyroid carcinoma and atypical parathyroid adenoma, at the time of the recruiting visit.
4. Continuous and updated prospective collection of patients' data over time, starting from the first recruiting visit up to 10 years after the recruitment in the study.
5. Evaluation of the prevalence and incidence of parathyroid carcinoma and atypical parathyroid adenoma in Italy, both as sporadic disease or in the context of genetic disorders.
6. Clinical, histological and biochemical characterization of parathyroid carcinoma vs atypical parathyroid adenoma, to assess features and aspects that distinguish these two kinds of tumors and may help in the differential diagnosis.
7. Evaluation of short-term and long-term response to therapies in patients with parathyroid carcinoma and in patients with atypical parathyroid adenoma to assess possible differences between these two types of cancer and, thus, to design tailored clinical and therapeutic managements for patients.
8. Evaluation of short-term and long-term response to therapies in sporadic forms vs genetic forms of parathyroid carcinoma and atypical parathyroid adenoma, to assess possible differences between these two different forms of diseases and, thus, to design tailored clinical and therapeutic managements for patients.
C. Study population:
The study will include two independent cohorts of female and male patients of any age, one including patients who developed parathyroid carcinoma (cohort 1) and one including patients who developed atypical parathyroid adenoma (cohort 2), both as sporadic cancer or in the context of genetic diseases.
The study does not include either any control group/comparison group or healthy volunteers.
Given the extreme rarity of parathyroid carcinoma and atypical parathyroid adenoma, we estimate that we will be able to include in the study a minimum of 100 and a maximum of 300 patients affected by parathyroid carcinoma or atypical parathyroid adenoma during the 10 years of the study.
Inclusion criteria
* Cohort 1: parathyroid carcinoma
* Cohort 2: atypical parathyroid adenoma Exclusion criteria
* None
D. Study design and setting:
Non-profit, multicenter, national, retro-prospective, observational study, consisting in the design, creation, management and analysis of an Italian database of patients with parathyroid carcinoma or atypical parathyroid adenoma.
The study will last 10 years. The enrollment of patients with parathyroid carcinoma or atypical parathyroid adenoma, the inclusion in the database with retrospective collection of their clinical data, and the subsequent prospective collection of clinical follow-up data will take place throughout the duration of the study. For the retrospective collection, retrospective data on parathyroid carcinoma or atypical parathyroid adenoma will be retrieved from patient's medical records, at the time of the medical visit that the patient will carry out at the Clinical Center for the evaluation of his/her parathyroid disease, regardless of inclusion in this study. Prospective data relating to the tumor follow-up will be collected during the subsequent medical follow-up visits, scheduled for each patient as part of the clinical management of his/her parathyroid disease, regardless of inclusion in this study.
Being an observational study, this study itself does not involve the administration of any drug, nor the use of any medical device, nor does it involve additional medical visits, clinical analyses or care procedures in addition to those conventionally scheduled for the clinical and therapeutic management of patient affected by parathyroid carcinoma or atypical parathyroid adenoma. No participant biospecimens of any type will be collected and retained to perform this study. Pharmacological treatments and parathyroid surgery, for which data on response to therapy and peri-operative and post-operative outcomes will be collected in the database during the study, are those that are conventionally administered and performed in patients with parathyroid carcinoma or atypical parathyroid adenoma in the context of treatment of their pathology, regardless of their inclusion in this observational study.
All data will be collected anonymously, and they will be analyzed as aggregates. Data collected in the database will be, first, processed using descriptive statistics, such as frequency tables for categorical data, median and quartiles for quantitative data on ordinal scales and mean and standard deviation for quantitative data on metric scales. Secondly, the correlations between variables will be evaluated using the Pearson correlation index in the case of continuous variables and the chi-square test for categorical variables.
E. Data and variables:
Data collected in the database will include (if available in patient's medical records):
* Demographics (sex, year of birth)
* Family history of parathyroid carcinoma/atypical parathyroid adenoma or other parathyroid diseases in first-degree relatives
* Lifestyle habits (i.e smoke, alcohol intake)
* History of neck irradiation
* Clinical history and therapy of hyperparathyroidism prior to diagnosis of parathyroid carcinoma/atypical parathyroid adenoma
* Presence of comorbidities
* Age at diagnosis of parathyroid carcinoma/atypical parathyroid adenoma, type of diagnosis, genetic test (if performed)
* Clinical manifestations of parathyroid carcinoma/atypical parathyroid adenoma (i.e hypercalcemia, nephrolithiasis, nephrocalcinosis, bone mass loss, fragility fracture, bone pain, radiological findings of skeletal complaints, gastrointestinal manifestations)
* Pre-operative instrumental screening of the neck (neck ultrasounds, parathyroid scintigraphy with 99mTc-Sestamibi, neck CT scan, 11C-choline PET/CT, 11C-methionin PET/CT, 18F-FDG-PET/CT)
* Pre-operative biochemical measurements of parameters of parathyroid function and of bone and mineral metabolism
* Pre-operative DXA evaluation of bone status
* Pre-operative identification of lymph node and/or distant metastases
* Pharmacological therapies
* Surgical intervention (age, type, clear margins, removed lymph nodes, complications, perioperative mortality, etc)
* Post-operative histological analysis of resected tumor (surrounding tissue and vascular invasion, Ki67 index, mitotic activity, nuclear atypia, aneuploidy, immunostaining of parafibromin and other specific proteins)
* TMN tumor staging
* Somatic genetic screening of resected tumor
* Post-operative clinical follow-up (serum calcium normalization, post-operative hypoparathyroidism, episodes of hypocalcemia, episodes of hypophosphatemia, hungry bone syndrome, disease persistence, tumor recurrence, etc)
* Post-operative biochemical measurements of parameters of parathyroid function and of bone and mineral metabolism (the first check-up after parathyroid surgery, and subsequent follow-up measurements)
* Post-operative instrumental screening of the neck (neck ultrasounds, parathyroid scintigraphy with 99mTc-Sestamibi, neck CT scan, 11C-choline PET/CT, 11C-methionin PET/CT, 18F-FDG-PET/CT)
* Post-operative DXA evaluation of bone status
* Death as a consequence of carcinoma/atypical parathyroid adenoma (age of death, cause)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Parathyroid Gland Carcinoma
Parathyroid Gland Atypical Adenoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with parathyroid carcinoma
Male and female patients of any age who developed parathyroid carcinoma. The study does not include any type of intervention
No interventions assigned to this group
Patients with atypical parathyroid adenoma
Male and female patients of any age who developed atypical parathyroid adenoma The study does not include any type of intervention
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cohort 1: parathyroid carcinoma
* Cohort 2: atypical parathyroid adenoma
* Cohort 2: atypical parathyroid adenoma
Exclusion Criteria
None
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
U.O.C. Endocrinologia, Azienda Ospedaliero Universitaria Policlinico Consorziale, Università degli Studi di Bari "Aldo Moro"
Bari, , Italy
Site Status
NOT_YET_RECRUITING
UOC Endocrinologia e Prevenzione e Cura del Diabete, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum Università di Bologna
Bologna, , Italy
Site Status
NOT_YET_RECRUITING
Endocrinologia e Diabetologia, Azienda Ospedaliero-Universitaria di Cagliari, Presidio Ospedaliero Policlinico di Monserrato
Cagliari, , Italy
Site Status
NOT_YET_RECRUITING
UO Endocrinologia e Malattie del Ricambio, Azienda Ospedaliero Universitaria di Ferrara, Sezione di Endocrinologia, Geriatria e Medicina Interna, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara
Ferrara, , Italy
Site Status
RECRUITING
SOD Malattie del Metabolismo Minerale ed Osseo, Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
Site Status
RECRUITING
Unità di Chirurgia Endocrina, Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
Site Status
NOT_YET_RECRUITING
Ospedale Casa Sollievo della Sofferenza
Foggia, , Italy
Site Status
NOT_YET_RECRUITING
Clinica Endocrinologica, Dipartimento di Medicina Interna e Specialità Mediche (DiMI), IRCCS Ospedale Policlinico San Martino, Università di Genova
Genova, , Italy
Site Status
NOT_YET_RECRUITING
Clinica Pediatrica ed Endocrinologia, IRCCS Ospedale Pediatrico Giannina Gaslini
Genova, , Italy
Site Status
NOT_YET_RECRUITING
U.O.S.D. Centro Malattie Rare · Dipartimento di Pediatria IRCCS Ospedale Pediatrico Giannina Gaslini
Genova, , Italy
Site Status
NOT_YET_RECRUITING
UOC di Endocrinologia, AOU Policlinico G. Martino, Dipartimento di Patologia Umana DETEV, Università di Messin
Messina, , Italy
Site Status
NOT_YET_RECRUITING
Dipartimento di Malattie Endocrino-Metaboliche, IRCCS Istituto Auxologico Italiano
Milan, , Italy
Site Status
NOT_YET_RECRUITING
Endocrinologia Infantile, UOU di Pediatria, IRCCS Ospedale San Raffaele
Milan, , Italy
Site Status
NOT_YET_RECRUITING
IRCCS Ospedale San Raffaele
Milan, , Italy
Site Status
NOT_YET_RECRUITING
SC Endocrinologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, , Italy
Site Status
NOT_YET_RECRUITING
Dipartimento di Medicina Clinica e Chirurgia; Unità di Endocrinologia, Diabetologia e Andrologia; Università degli Studi di Napoli Federico II
Napoli, , Italy
Site Status
RECRUITING
UOC di Endocrinologia e Malattie del Metabolismo, AOU Università degli Studi della Campania Luigi Vanvitelli
Napoli, , Italy
Site Status
NOT_YET_RECRUITING
SCDU Endocrinologia Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
Novara, , Italy
Site Status
NOT_YET_RECRUITING
Endocrinologia, Clinica Polispecialistica San Carlo
Paderno Dugnano, , Italy
Site Status
NOT_YET_RECRUITING
Unità di Chirurgia Endocrina, Dipartimento di Chirurgia, Oncologia e Gastroenterologia, Università di Padova
Padua, , Italy
Site Status
NOT_YET_RECRUITING
UOC Endocrinologia, DIMED, Azienda Ospedaliero-Universitaria di Padova
Padua, , Italy
Site Status
NOT_YET_RECRUITING
Unità Operativa Endocrinologia 2, Azienda Ospedaliera Universitaria Pisana
Pisa, , Italy
Site Status
NOT_YET_RECRUITING
Dipartimento di Medicina Sperimentale, "Sapienza" Università di Roma, Roma - UOC Endocrinologia, Policlinico Umberto I di Roma
Roma, , Italy
Site Status
NOT_YET_RECRUITING
Unità di Endocrinologia e Andrologia, Dipartimento di Medicina Clinica e Molecolare, AOU Sant'Andrea, Centro di eccellenza ENETS, Università Sapienza di Roma
Roma, , Italy
Site Status
NOT_YET_RECRUITING
UOC Patologie osteo-metaboliche e della tiroide, Fondazione Policlinico universitario Campus Bio-Medico
Roma, , Italy
Site Status
NOT_YET_RECRUITING
UOC di Endocrinologia, Diabetologia e Andrologia Medica, IRCCS Humanitas Research Hospital
Rozzano, , Italy
Site Status
NOT_YET_RECRUITING
Donatello Bone Clinic, Casa di Cura Villa Donatello
Sesto Fiorentino, , Italy
Site Status
RECRUITING
Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Policlinico Santa Maria delle Scotte, Università di Siena
Siena, , Italy
Site Status
NOT_YET_RECRUITING
SCDU Endocrinologia Diabetologia e Malattie del Metabolismo, AOU Città della Salute e della Scienza di Torino, Università di Torino
Torino, , Italy
Site Status
NOT_YET_RECRUITING
SCDU Endocrinologia Oncologica, AOU Città della Salute e della Scienza di Torino, Università di Torino
Torino, , Italy
Site Status
NOT_YET_RECRUITING
IRCCS Materno-Infantile Burlo Garofolo
Trieste, , Italy
Site Status
NOT_YET_RECRUITING
SOC Endocrinologia, Azienda Sanitaria-Universitaria Friuli Centrale
Udine, , Italy
Site Status
NOT_YET_RECRUITING
UOS di Endocrinologia, Policlinico GB Rossi, Azienda Ospedaliera Universitaria Integrata di Verona
Verona, , Italy
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23354_oss
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of Different Diagnostic Therapeutic Strategies in Patients with Thyroid Pathology
NCT06779747
RECRUITING
interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
NCT01774279
UNKNOWN
No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid Cancer: Insight From Middle Eastern Cohort
NCT07115810
COMPLETED
Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer
NCT01074684
COMPLETED
Studies of Inherited Diseases of Metabolism
NCT00001345
COMPLETED
Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Patients With Advanced Carcinoma
NCT05593744
COMPLETED
Observational Study Analysing the Transcriptome and Mutational Status of Thyroid Carcinomas of Follicular Origin with Different Degrees of Malignancy
NCT06878534
RECRUITING
GETNE Registration of Thyroid Cancer
NCT03765333
RECRUITING
Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities
NCT04671719
COMPLETED
Taiwanese Anaplastic Thyroid Cancer Registry
NCT07138261
NOT_YET_RECRUITING
Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
NCT02156362
UNKNOWN
NA
Tunisian Clinical Registry on Hypoparathyroidism and Pseudo-hypoparathyroidism
NCT06445036
NOT_YET_RECRUITING
Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism
NCT00004661
COMPLETED
Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland
NCT03516747
WITHDRAWN
NA
Palopegteriparatide in Chronic Hypoparathyroidism
NCT07299838
COMPLETED
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
NCT00094055
COMPLETED
PHASE2
Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism
NCT04146259
COMPLETED
Active Surveillance of Papillary Thyroid Microcarcinoma
NCT02609685
RECRUITING
NA
Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer
NCT05796258
COMPLETED
Review of Multimodality Management of Anaplastic Thyroid Cancer
NCT00280852
COMPLETED
PTeye in Parathyroid Adenoma
NCT06913296
RECRUITING
"Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases"
NCT02636075
UNKNOWN
PET-TC in Thyroid Evaluation
NCT06852144
ENROLLING_BY_INVITATION
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
NCT05819593
NOT_YET_RECRUITING